Tailored drug cocktails aim to outsmart resistant esophageal cancer
NCT ID NCT07653451
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether matching drug combinations to a patient's tumor genetics can help when standard immunotherapy stops working. About 90 people with advanced esophageal cancer will get one of three treatment pairs based on their cancer's molecular profile. The goal is to see if these personalized approaches can slow or stop the cancer from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Afatinib, Toripalimab, Dalpiciclib, Pyrotinib, Camrelizumab, Apatinib
- What this could lead to
- If successful, this could offer new treatment options for people with advanced esophageal cancer that no longer responds to immunotherapy, potentially improving survival.
- What could go wrong
- This is a small, early-phase trial (90 participants) and the treatments may not work for everyone. Side effects from the drug combinations could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads